Amgen Inc. (NASDAQ:AMGN) Shares Sold by Investment Advisory Services Inc. TX ADV

Investment Advisory Services Inc. TX ADV decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,238 shares of the medical research company’s stock after selling 62 shares during the quarter. Investment Advisory Services Inc. TX ADV’s holdings in Amgen were worth $1,632,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Beck Mack & Oliver LLC grew its position in Amgen by 0.7% during the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock valued at $1,205,000 after buying an additional 34 shares during the period. Continuum Advisory LLC increased its stake in shares of Amgen by 0.7% in the 4th quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company’s stock valued at $1,343,000 after purchasing an additional 35 shares in the last quarter. Octavia Wealth Advisors LLC raised its holdings in Amgen by 1.5% in the 1st quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company’s stock worth $759,000 after purchasing an additional 35 shares during the period. Trillium Asset Management LLC boosted its position in Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock worth $237,000 after purchasing an additional 37 shares in the last quarter. Finally, Affinity Capital Advisors LLC grew its holdings in Amgen by 4.5% in the first quarter. Affinity Capital Advisors LLC now owns 861 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 37 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president now owns 8,162 shares of the company’s stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AMGN shares. UBS Group reissued a “neutral” rating and issued a $315.00 price target (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Royal Bank Of Canada reduced their target price on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Piper Sandler dropped their price target on Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a research report on Friday, May 16th. Finally, Morgan Stanley reaffirmed an “equal weight” rating on shares of Amgen in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $309.22.

Amgen Stock Up 1.0%

Shares of NASDAQ:AMGN opened at $280.35 on Thursday. The firm has a market capitalization of $150.75 billion, a PE ratio of 25.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.51. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. The firm’s 50-day moving average is $280.99 and its two-hundred day moving average is $286.00.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the prior year, the company earned $3.96 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.